When was CUTISS founded?

CUTISS was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is CUTISS located?

CUTISS is headquartered in Zurich, Switzerland.

Who is the current CEO of CUTISS?

Daniela Marino of CUTISS. They have also founded 1 company.

How many employees does CUTISS have?

As of Sep 30, 2026, the latest employee count at CUTISS is 67.

Is CUTISS a funded company?

CUTISS is a funded company, having raised a total of $157M across 13 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 01, 2017.

When was the latest funding round of CUTISS?

CUTISS's latest funding was a $***** Series C round on Sep 10, 2025, with participation from 0 investor.

Where does CUTISS rank among its competitors?

CUTISS ranks 3rd amongst 35 active competitors, of which 6 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was TYBR Health, which secured $30M in Jul, 2026.

Who are the top competitors of CUTISS?

CUTISS's top competitors include Humacyte, AxoGen and Acera Surgical. Among them, TYBR Health secured the most recent funding round in July, 2026.

CUTISS - 2026 Company Profile, Team, Funding & Competitors

Company Details

Company developing personalized skin tissue therapeutics for skin defect treatments. The company is pioneering a novel approach to personalized skin treatment, leveraging its proprietary technology to create customized skin grafts for various medical applications. With a strong foundation in regenerative medicine and tissue engineering, CUTISS aims to revolutionize skin surgery and improve patient outcomes.

Website: cutiss.swiss
Social
Email ID: *****@cutiss.swiss
Phone Number: +41 **********

Key Metrics

Founded Year

2017

Location

Zurich, Switzerland

Stage

Series C

Total Funding

$157M in 13 rounds

Latest Funding Round

Series C, Sep 10, 2025, $*****

Investors

Giammaria Giuliani & 16 more

Ranked

3^rd among 35 active competitors

Employee Count

67 as on Sep 30, 2026

Similar Companies

Humacyte & 38 more

View CUTISS's full profile

CUTISS has raised a total funding of $157M over 13 rounds. Its first funding round was on Sep 01, 2017. CUTISS has 16 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of CUTISS:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 10, 2025	5599094	Series C	6112266	8596992	5102627	1126388
May 21, 2024	9891838	Series C	4103348	1478200	4324436	GISEV & 3 more
Jan 25, 2022	8086949	Grant (prize money)	9854516	5505909	9711903	4986580

Access funding benchmarks and valuations. Sign up today!

View details of CUTISS's funding rounds and investors

The founders of CUTISS is Daniela Marino. Daniela Marino is the CEO of CUTISS.

Here are the details of CUTISS's key team members:

Daniela Marino: Co-Founder & CEO of CUTISS.

View details of CUTISS's Founder profiles and Board Members

CUTISS's employee count trend

CUTISS has 67 employees as of Sep 26. Here is CUTISS's employee count trend over the years:

Uncover CUTISS's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CUTISS include Humacyte, AxoGen and Acera Surgical. Here is the list of Top 10 competitors of CUTISS, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Humacyte 2004, Durham (United States), Public	Provider of human tissue-based products for vascular disease	$425M	Access Industries, Fresenius Medical Care ... & 15 others	66/100
2nd	AxoGen 2002, Alachua (United States), Public	Developer of therapies for the repair of peripheral nerve injuries	$62.4M	Oberland Capital, Cardinal Partners & 10 others	65/100
3rd	CUTISS 2017, Zurich (Switzerland), Series C	Company developing personalized skin tissue therapeutics for skin defect treatments	$157M	Venionaire Capital, EIC Fund & 15 others	53/100
4th	Acera Surgical 2013, St. Louis (United States), Acquired	Provider of synthetic electrospun scaffolds for regenerative medical applications	$6.32M	St. Louis Arch Angels, Missouri Technology ... & 1 others	57/100
5th	TYBR Health 2020, Houston (United States), Series A	Provider of regenrative medicine for post surgical scarring	$38.4M	Vensana Capital, Y Combinator & 4 others	56/100
6th	Tissue Regenix 2006, Swillington (United Kingdom), Public	Developer of regenerative medical devices by using cell technology	-	Harwood Capital, IP Group & 2 others	53/100
7th	Epibone 2013, Brooklyn (United States), Series B	Developer of patient‑specific bone and cartilage grafts	$48.6M	Kendall Capital Partners, MBX Capital & 25 others	51/100
8th	Aroa Biosurgery 2008, Mangere (New Zealand), Public	Developer of medical and surgical products for soft tissue reconstruction	-	Alium Capital, Cure Kids Ventures & 2 others	51/100
9th	Heartseed 2015, Shinjuku City (Japan), Public	Developer of myocardial regenerative medicine for treating heart diseases	$76.7M	Sumitomo Mitsui Trust Holdings, SBI Group ... & 18 others	47/100
10th	Solsys Medical 1999, Norfolk (United States), Acquired	Provider of human skin allograft and dressing for wound care	$37.2M	SWK Holdings, 1315 Capital & 1 others	43/100